Two opposing roles of O-glycans in tumor metastasis

Trends in Molecular Medicine

Volumn 18, Issue 4, 2012, Pages 224-232

  Tsuboi, Shigeru ^a,b   Hatakeyama, Shingo ^b   Ohyama, Chikara ^b   Fukuda, Minoru ^c  

^a Oyokyo Kidney Research Institute   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; INTEGRIN; O GLYCAN DERIVATIVE; O GLYCOSYLATED PROTEIN; O MANNOSYL GLYCAN DERIVATIVE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

CANCER CELL; CANCER INVASION; CHEMICAL STRUCTURE; HUMAN; IMMUNE SYSTEM; METASTASIS; NATURAL KILLER CELL; REVIEW;

ANIMALS; HUMANS; INTEGRINS; KILLER CELLS, NATURAL; NEOPLASM METASTASIS; POLYSACCHARIDES; SIGNAL TRANSDUCTION;

EID: 84859427921     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.02.001     Document Type: Review

References (81)

1. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
2. Dennis J.W., et al. UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochim. Biophys Acta. 2002, 1573:414-422.
3. Yoshimura M., et al. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:8754-8758.
4. Suzuki-Anekoji M., et al. HNK-1 glycan functions as a tumor suppressor for astrocytic tumor. J. Biol. Chem. 2011, 286:32824-32833.
5. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 2006, 7:599-604.
6. Maemura K., Fukuda M. Poly-N-acetyllactosaminyl O-glycans attached to leukosialin. The presence of sialyl Le(x) structures in O-glycans. J. Biol. Chem. 1992, 267:24379-24386.
7. Lofling J., Holgersson J. Core saccharide dependence of sialyl Lewis X biosynthesis. Glycoconj. J. 2009, 26:33-40.
8. Stone E.L., et al. Glycosyltransferase function in core 2-type protein O glycosylation. Mol. Cell Biol. 2009, 29:3770-3782.
9. Gilbert S.F. Ageing and cancer as diseases of epigenesis. J. Biosci. 2009, 34:601-604.
10. Varki A., et al. Glycosylation changes in cancer. Essentials of Glycobiology 2009, 617-632. Cold Spring Harbor Laboratory Press. 2nd edn. A. Varki (Ed.).
11. Hedlund M., et al. α2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res. 2008, 68:388-394.
12. Wang F.L., et al. High expression of alpha 2,3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer. Cancer Detect. Prev. 2009, 32:437-443.
13. Cohen M., et al. Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J. Immunol. 2010, 185:5869-5878.
14. Iwai T., et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4572-4577.
15. Yeh J.C., et al. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J. Biol. Chem. 1999, 274:3215-3221.
16. Schwientek T., et al. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. J. Biol. Chem. 1999, 274:4504-4512.
17. Stalnaker S.H., et al. Mammalian O-mannosylation: unsolved questions of structure/function. Curr. Opin. Struct. Biol. 2011, 21:603-609.
18. Chiba A., et al. Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J. Biol. Chem. 1997, 272:2156-2162.
19. Endo T. O-Mannosyl glycans in mammals. Biochim. Biophys Acta. 1999, 1473:237-246.
20. Yoshida-Moriguchi T., et al. O-Mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 2010, 327:88-92.
21. Bao X., et al. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:12109-12114.
22. Barresi R., Campbell K.P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 2006, 119:199-207.
23. Yoshida A., et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 2001, 1:717-724.
24. Kanagawa M., et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 2004, 117:953-964.
25. Inamori K., et al. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 2012, 335:93-96.
26. Yousefi S., et al. Increased UDP-GlcNAc:Gal beta 1-3GaLNAc-R (GlcNAc to GaLNAc) beta-1, 6-N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. J. Biol. Chem. 1991, 266:1772-1782.
27. Shimodaira K., et al. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res. 1997, 57:5201-5206.
28. Machida E., et al. Clinicopathological significance of core 2 beta1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res. 2001, 61:2226-2231.
29. Hagisawa S., et al. Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 2005, 15:1016-1024.
30. Hatakeyama S., et al. Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int. J. Cancer 2010, 127:1052-1059.
31. Tsuboi S., et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 2011, 30:3173-3185.
32. Vavasseur F., et al. O-Glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur. J. Biochem. 1994, 222:415-424.
33. Vavasseur F., et al. Synthesis of O-glycan core 3: characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines. Glycobiology 1995, 5:351-357.
34. Laubli H., Borsig L. Selectins promote tumor metastasis. Semin. Cancer Biol. 2010, 20:169-177.
35. St Hill C.A. Interactions between endothelial selectins and cancer cells regulate metastasis. Front. Biosci. 2012, 17:3233-3251.
36. Sozzani P., et al. Is Sialyl Lewis x antigen expression a prognostic factor in patients with breast cancer?. Int. J. Surg. Pathol. 2008, 16:365-374.
37. Yusa A., et al. Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewis x expression and accelerates proliferation of colon cancer cells. Cancer Res. 2010, 70:4064-4073.
38. Tsuboi S., Fukuda M. Roles of O-linked oligosaccharides in immune responses. Bioessays 2001, 23:46-53.
39. Lakshminarayanan V., et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:261-266.
40. Benson V., et al. Glycosylation regulates NK cell-mediated effector function through PI3K pathway. Int. Immunol. 2010, 22:167-177.
41. Bierhuizen M.F., Fukuda M. Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:9326-9330.
42. Skrincosky D., et al. Altered Golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans. J. Biol. Chem. 1997, 272:22695-22702.
43. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 2008, 9:495-502.
44. Rabinovich G.A., et al. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand. J. Immunol. 2007, 66:143-158.
45. Yang R.Y., et al. Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med. 2008, 10:e17.
46. Saegusa J., et al. Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis. Am. J. Pathol. 2009, 174:922-931.
47. Rubinstein N., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection. Cancer Cell 2004, 5:241-251.
48. Demotte N., et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008, 28:414-424.
49. Dardalhon V., et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol. 2010, 185:1383-1392.
50. Peng W., et al. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 2008, 68:7228-7236.
51. van Kooyk Y., Rabinovich G.A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol. 2008, 9:593-601.
52. Zwirner N.W., et al. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr. Pharm. Des. 2010, 16:255-267.
53. Zaia Povegliano L., et al. Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J. Gastrointest. Cancer 2011, 42:217-221.
54. Guerra N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
55. Zafirova B., et al. Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity 2009, 31:270-282.
56. Groh V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
57. Doubrovina E.S., et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 2003, 171:6891-6899.
58. Clayton A., et al. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 2008, 180:7249-7258.
59. Oppenheim D.E., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 2005, 6:928-937.
60. Fuertes M.B., et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 2008, 180:4606-4614.
61. Storr S.J., et al. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 2008, 18:456-462.
62. Huang M.C., et al. C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells. Oncogene 2006, 25:3267-3276.
63. Lee S.H., et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J. Biol. Chem. 2009, 284:17157-17169.
64. Basson M.D. An intracellular signal pathway that regulates cancer cell adhesion in response to extracellular forces. Cancer Res. 2008, 68:2-4.
65. Clement M., et al. Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J. Cell Sci. 2004, 117:5059-5069.
66. Isaji T., et al. N-Glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function. J. Biol. Chem. 2006, 281:33258-33267.
67. Gu J., Taniguchi N. Potential of N-glycan in cell adhesion and migration as either a positive or negative regulator. Cell Adhes. Migr. 2008, 2:243-245.
68. Kariya Y., Gu J. N-Glycosylation of ss4 integrin controls the adhesion and motility of keratinocytes. PLoS ONE 2011, 6:e27084.
69. An G., et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J. Exp. Med. 2007, 204:1417-1429.
70. Muntoni F., et al. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008, 5:627-632.
71. Peyrard M., et al. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:598-603.
72. Grewal P.K., et al. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat. Genet. 2001, 28:151-154.
73. Longman C., et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum. Mol. Genet. 2003, 12:2853-2861.
74. Sasaki K., et al. Expression cloning of cDNA encoding a human beta-1,3-N-acetylglucosaminyltransferase that is essential for poly-N-acetyllactosamine synthesis. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14294-14299.
75. Larsen M., et al. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 18:463-471.
76. Ido H., et al. Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10. J. Biol. Chem. 2004, 279:10946-10954.
77. Yoneyama T., et al. Fer kinase regulates cell migration through alpha-dystroglycan glycosylation. Mol. Biol. Cell 2012, 10.1091/mbc.E11-06-0517.
78. Uemura T., et al. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene 2009, 28:1218-1229.
79. Shiozaki K., et al. Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J. Biol. Chem. 2011, 286:21052-21061.
80. Wagner K.W., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
81. Freire-de-Lima L., et al. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17690-17695.